# Ribociclib and Gemcitabine Hydrochloride in Treating Patients With Advanced or Metastatic Solid Tumors

> **NCT03237390** · PHASE1 · COMPLETED · sponsor: **Mayo Clinic** · enrollment: 43 (actual)

## Conditions studied

- Advanced Malignant Solid Neoplasm
- Metastatic Malignant Solid Neoplasm

## Interventions

- **DRUG:** Gemcitabine Hydrochloride
- **OTHER:** Laboratory Biomarker Analysis
- **OTHER:** Pharmacological Study
- **DRUG:** Ribociclib

## Key facts

- **NCT ID:** NCT03237390
- **Lead sponsor:** Mayo Clinic
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-01-04
- **Primary completion:** 2022-05-17
- **Final completion:** 2022-05-17
- **Target enrollment:** 43 (ACTUAL)
- **Last updated:** 2023-01-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03237390

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03237390, "Ribociclib and Gemcitabine Hydrochloride in Treating Patients With Advanced or Metastatic Solid Tumors". Retrieved via AI Analytics 2026-05-22 from https://api.ai-analytics.org/clinical/NCT03237390. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*